{"id":"W4386102508","doi":"10.1097/01.hs9.0000975836.58931.97","title":"PB2276: MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI-CD20 ANTIBODIES VS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Obinutuzumab; Medicine; Ibrutinib; Lenalidomide; Rituximab; Internal medicine; Oncology; Follicular lymphoma; Mantle cell lymphoma; Chronic lymphocytic leukemia; Salvage therapy; Phases of clinical research; Idelalisib; Lymphoma; Clinical trial; Chemotherapy; Leukemia; Multiple myeloma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007347649,0.0005419354,0.001734554,0.000382524,0.0001262041,0.00004384052,0.0003692929,0.0003556925,0.001128163],"category_scores_gemma":[0.0009648347,0.0003656968,0.0002390721,0.00173919,0.0004013566,0.0002564788,0.0002563121,0.0003879709,0.0002430891],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.006687527,"about_ca_system_score_gemma":0.01300137,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001102329,"about_ca_topic_score_gemma":0.0002983369,"domain_scores_codex":[0.9949292,0.0002219277,0.00109001,0.000872205,0.001765973,0.001120711],"domain_scores_gemma":[0.9972316,0.0005571602,0.0003877991,0.001101479,0.0003524427,0.0003695338],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9587897,0.006759949,0.002324485,0.002359898,0.0006620242,0.01033584,0.001364078,0.00008516418,0.0006409895,0.00005986824,0.008511226,0.00810676],"study_design_scores_gemma":[0.9699979,0.008523464,0.003528179,0.001734115,0.0002587584,0.0001704957,0.0009382792,0.004933512,0.002512469,0.00001071598,0.006859922,0.0005322284],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9953122,0.0002873009,0.00006306699,0.0002206457,0.0002823352,0.002743924,0.00009079334,0.0002003548,0.0007994191],"genre_scores_gemma":[0.9894922,0.0002683053,0.0008767716,0.0001118977,0.0002478284,0.0001418659,0.0002787064,0.0001494524,0.008432989],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01120814,"threshold_uncertainty_score":0.9998795,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03128032831111953,"score_gpt":0.3233636286600862,"score_spread":0.2920833003489667,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}